Directorate Change

RNS Number : 8214U

Cambridge Cognition Holdings PLC

03 August 2022

 

3 August 2022

Cambridge Cognition Holdings Plc

("Cambridge Cognition", the "Company" or the "Group")

Directorate Change

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that further to the announcement of 6 April 2022, Stephen Symonds, Chief Financial Officer, has been appointed to the Board of Cambridge Cognition as an Executive Director with immediate effect.

Stephen was previously the CFO of Envigo, a provider of pre-clinical services to the pharmaceutical industry, where he spent eight years.  Prior to that, Stephen spent a decade with KPMG, working on a wide-ranging portfolio of clients.  

Steven Powell, Chairman of the Company, commented: "We are delighted that Stephen is joining the Board. He has extensive relevant experience and has fitted in very well with the team since joining the Company in April this year."

Additional Information in respect of the AIM Rules

The following information regarding the appointment of Stephen Daniel Symonds, aged 47, is disclosed under Schedule Two paragraph (g) of the AIM Rules for Companies:

Current Directorships	Previous Directorships (within the last five years)
	Centralabs Clinical Research Limited
	Covance Consulting Limited
	Covance CRS Analytics Limited
	Covance CRS Developments Limited
	Covance CRS International Limited
	Covance Pharma Consulting Limited
	Envigo CRS (Switzerland) Limited
	Envigo CRS GmbH
	Envigo CRS Israel Limited
	Envigo CRS SA
	Envigo CRS Switzerland Limited
	Envigo Holdings Limited
	Envigo Monitoring Limited
	Envigo RMS (UK) Limited
	Envigo RMS BV
	Envigo RMS GmbH
	Envigo RMS India Private Limited
	Envigo RMS Israel Limited
	Envigo RMS Sarl
	Envigo RMS SL
	Envigo RMS Srl
	Envigo Ventures Limited
	Harlan Eurasia Holdings Limited
	Harlan Europe Holdings Limited
	HIH Limited
	Huntingdon Consulting Engineers Limited
	Huntingdon Research Centre Limited
	Labcorp Research Limited
	Labcorp UK Limited
	Paragon Global Services Limited
	Pathfinder Clinical Development Limited
	Pathfinder Nominees Limited
	Servicepharm Limited

As at the date of this announcement, Stephen Symonds holds 22,950 ordinary shares in the Company representing 0.07% of the Company's issued share capital. In addition, Stephen holds an interest in 152,671 options over ordinary shares of the Company.

Save as set out above there are no further disclosures pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies in respect of the appointment of Stephen Symonds.

For further information, please contact:

Cambridge Cognition Holdings Plc	Tel: [phone]
Matthew Stork, Chief Executive Officer	[e-mail]
Stephen Symonds, Chief Financial Officer
Panmure Gordon (UK) Ltd (NOMAD and Joint Broker)	Tel: [phone]
Freddy Crossley / Emma Earl / Mark Rodgers	(Corporate Advisory)
Rupert Dearden	(Corporate Broking)
Dowgate Capital Limited (Joint Broker)	Tel: [phone]
David Poutney / James Serjeant
IFC Advisory Ltd (Financial PR and IR)	Tel: [phone]
Tim Metcalfe / Graham Herring / Zach Cohen	[e-mail]

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit  www.cambridgecognition.com

 

END

 

 

BOAKZGGRFFMGZZM